Search
multi
plo®

rapid TP/HIV/HCV antibody test

Accurate, rapid simultaneous detection of antibodies to HIV-1/2, syphilis, and Hepatitis C virus (HCV) in whole blood, serum, and plasma specimens.

One Test – More Answers

The Multiplo® Rapid TP/HIV/HCV Antibody Test enables simultaneous detection of Human Immunodeficiency Virus Type 1 and Type 2 (anti-HIV-1/2), total antibodies to Treponema pallidum (syphilis), and antibodies to Hepatitis C virus (anti-HCV), using MedMira’s Rapid Vertical Flow (RVF) Technology™. Its simple and proven three-step procedure delivers fast, reliable results.

  • Immediate results

    No waiting time, results do not vanish.

  • Reliable accuracy

    Achieves high testing performance across multiple specimen matrices.

  • Multiplex testing

    Multiple diseases tested on a single cartridge using one blood sample.

  • No equipment or refrigeration required

    Stores at room temperature (2–30 °C / 35–86 °F) with a 12-month shelf life.

  • Easy to use and interpret

    Simple procedure with instant, easy-to-read results, no special training required.

  • Ideal for any setting

    Works with serum, plasma, and whole blood (venipuncture or fingerstick).

multiplo TP HIV HCV logo
From sample to results

in three simple Steps

Testing doesn’t have to be complicated. Our intuitive three-step process ensures instant, consistent results with minimal effort.

add buffer from v2 to blue cap
Pour buffer

Pour buffer onto the InstantGold™ cap.

TP HIV HCV blood step2
Cap

Place the InstantGold™ cap on the cartridge.

TP HIV HCV blood step1
Add sample

Pour lysed blood specimen into the test cartridge.

For a similar procedure, watch the Multiplo® Rapid HBc/HIV/HCV Antibody Test video (Youtube, 3:16 min).

add buffer to blue cap scale
Cap & Pour buffer

Place InstantGold™ cap on the test &
 add buffer.

TP HIV HCV PlasmaSerum step2
Add specimen

Apply specimen to the centre of the test membrane.

TP HIV HCV PlasmaSerum step1
Pour buffer

Apply buffer to the test center.

For a similar procedure, watch the Multiplo® Rapid HBc/HIV/HCV Antibody Test video (Youtube, 2:36 min).

Explore your options with us

This product is available for international applications outside North America and the EU. For information regarding Multiplo® Rapid TP/HIV/HCV Antibody Test, including availability, ordering procedures, and technical documentation, please contact our team.

Related Products

Designed for use across POC settings, laboratories, academic institutions, and research environments.

Designed for use across POC settings, laboratories, academic institutions, and research environments.

Miriad is intended for laboratory, academic, and research use only, and is not for use in diagnostic procedures.

Learn more about our upcoming technology and products advancing through our development pipeline.

Frequently Asked Questions

To learn more about Multiplo® Rapid TP/HIV/HCV Antibody Test, please contact us.

What is RVF technology™?

RVF (Rapid Vertical Flow) is a flow-through technology that captures specific biomarkers from blood, serum, or plasma samples on a specialized membrane, delivering instant visual results.

Learn more

Why use a rapid test instead of a laboratory-based test?

Rapid tests provide valuable advantages across a range of environments, from point-of-care settings to research and laboratory workflows. They deliver results within minutes without relying on extensive infrastructure, specialized instruments, or highly trained personnel, which helps reduce costs and streamline testing processes. Modern rapid assays often demonstrate performance comparable to laboratory methods, making them a practical option for decentralized screening, high-throughput research studies, emergency situations, and programs that require immediate decision-making or broad accessibility.

Where to buy Multiplo® Rapid TP/HIV/HCV Antibody Test?
The Multiplo® Rapid TP/HIV/HCV Antibody Test is available exclusively for international use; our sales team can provide ordering details upon request. Meanwhile, the Miriad® Rapid TP/HIV/HCV Antibody Test is offered in the United States, Canada, the EU, and other regions, though strictly for research use only and not for diagnostic purposes.
Contact Us
Why use a combined test for TP, HIV, and HCV?

TP, HIV, and HCV are infections that commonly share transmission routes, especially in settings where unprotected sexual contact or exposure to infected blood may occur. Testing for all three markers in a single assay streamlines screening, reduces the need for multiple separate tests, and supports efficient workflows in both laboratory and point-of-care environments. A combined test simplifies sample handling while providing broad, reliable detection across these key infectious diseases. The Multiplo® Rapid TP/HIV/HCV Antibody Test enables effective screening through a straightforward three-step procedure, delivering dependable results with minimal hands-on time.

Are there alternative testing solutions available?

Yes. Our Multiplo® product line offers testing for several diseases within a single test cartridge and includes assays such as the Multiplo® Rapid TP/HIV Test, which holds regulatory approvals in Canada (home country approval). In addition, our Miriad® product line – available for research use only – provides further testing options, including assays capable of detecting TP/HIV/HCV.

Privacy Policy

Last updated: April 20, 2026

MedMira Inc. (“MedMira”, “we”, “us”, or “our”) is committed to protecting personal information in accordance with applicable privacy laws, including the Personal Information Protection and Electronic Documents Act (PIPEDA) in Canada, as well as applicable United States and international privacy requirements.

This Privacy Policy describes how we collect, use, disclose, and safeguard personal information through our website. Our website is primarily informational in nature and does not provide user accounts, applications, or diagnostic services.

Terms And Conditions Of Use

Please Read These Terms Carefully Before Using This Site. This website is provided by MedMira Inc. (MedMira) and may be used for informational purposes only. By using the site or downloading materials from the site, you agree to abide by the terms and conditions set forth in this notice. If you do not agree to abide by these terms and conditions do not use the site or download materials from the site.

Subscribe
Join our newsletter

Receive company updates, regulatory milestones, and event announcements.

By subscribing, you agree to our Privacy Policy and consent to receive updates.

Committed to quality
Certified & Proven Quality

Our quality management system is ISO 13485:2016 certified, compliant with the United States Food and Drug Administration’s current Good Manufacturing Practices (cGMP: Quality System Regulation Part 820 of CFR Title 21, Volume 8), European Union’s Directive 98/79/EC on in vitro diagnostic medical devices, and Health Canada Medical Device Regulations (SOR/98-282).

Additionally, we adhere to ISO 14971 (Application of Risk Management to Medical Devices) and ISO 2859 (Sampling Procedures for Inspection by Attributes). Certification and compliance to these requirements attests to our ability to maintain the highest standard of quality in medical device manufacturing, product development and corporate conduct.

Our products have been approved by regulators and UN agencies worldwide.

FDA

Health Canada

International Trade Centre (ITC)

Pan American Healtch Organization (PAHO)

UN Development Programme (UNDP)

UN Office for Project Services (UNOPS)

UN Office at Vienna (UNOV)

UN Population Fund (UNFPA)

United States Agency for International Development (USAID)

CFO & Head of Commercialization

Markus Meile

Markus joined MedMira in 2010, and moved into the role of Chief Financial Officer in 2014.

He previously served on the Company’s Board of Directors, as a member of the Audit Committee, and as the Senior Director of International Markets.

Prior to joining MedMira, Markus worked with a number of financial institutions in Switzerland, England, and Hong Kong. He holds a BSc from Royal Holloway University of London and has studied business management, strategic planning, investment and accounting at business school in Zurich. Previously, Markus worked in the medical device industry in Africa, Asia Pacific, and Europe.

He will combine his financial expertise with his broad range of international business knowledge to build financial and corporate strategies supporting MedMira’s continuing growth and increasing shareholder value.

Director of the Audit Committee, Nomination and Compensation Committee

Jianhe Mao

Jianhe Mao is the owner of Unipec, a consulting firm based in St. Gallen, Switzerland. Unipec focuses on helping European companies enter the Chinese market, through operational restructuring and ownership and management optimization.

In addition to leading Unipec, Mr. Mao is involved in several industrial projects and start-up ventures including Monsatec AG, a new company bridging the gap between laboratories and clinics with a cold plasma medical device. He serves on the boards of several European companies and is regarded as a trusted expert in legal cases, corporate corruption, operational turnarounds, and mergers and acquisitions.

Mr. Mao began his career as a project engineer and has gained experience in business development and real estate investment. He holds M.E. from Ruhr University Bochum.

CEO, Co-Founder & Co-Inventor

Hermes Chan, D.Sc. (h.c.)

Hermes Chan, our Chief Executive Officer and Co-Founder, leads our passionate and committed team in driving the strategic direction and growth of MedMira.

Hermes, who was named BioScience Innovator of the Year by The Economist in 2007, is the inventor of our patented rapid flow-through diagnostic technology platform.

Since the company’s inception in 1994 Hermes has held progressively senior management roles including Research Scientist, General Manager, Senior Vice President, and Chief Operating Officer.

Prior to creating MedMira, Hermes worked with another Canadian biotechnology company in the diagnostics research sector.

Chair member of the Audit Committee, Nomination and Compensation Committee

Steven Cummings

Mr. Steven Cummings is the Founder & President of Cambridge Financial Services, one of the leading full service accounting, tax, and business advisory firms in Nova Scotia.

Under Mr. Cummings leadership, Cambridge Financial has earned an enviable reputation among businesses and industry for a commitment to high standards. Along with his leadership responsibilities at Cambridge Financial Services, Mr. Cummings was engaged as MedMira’s interim Chief Financial Officer in 2007.

With more than 30 years of financial and entrepreneurial experience, Mr. Cummings is a frequent guest speaker on issues surrounding provincial taxation, taxation of seniors, and business ownership

Intellectual property

China

ZL02819646.5

Rapid Diagnostic Device and Assay

Intellectual property

European union

EP1417489

Rapid Diagnostic Device and Assay

EP1328811

HCV Mosaic Antigen Composition (2021)

Intellectual property

USA

9,164,087

Rapid Diagnostic Device, assay and multifunctional Buffer

9,086,410

Downward or vertical flow diagnostic device and assay

8,025,850

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,287,817

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,586,375

Rapid Diagnostic Device, Assay and Multifunctional Buffer

7,531,362

Rapid Diagnostic Device, Assay and Multifunctional Buffer

D706945

Diagnostic Device

D706466

Diagnostic Device

11,353,450

Analyte Detection Using Raman Spectroscopy

Intellectual property

Canada

CA2,493,616

Rapid Diagnostic Device, Assay and Multifunctional Buffer

CA2,740,902

Downward or Vertical Flow Diagnostic Device and Assay

CA2,949,634

Analyte Detection Using Raman Spectroscopy

MiROQ Vision

Handheld Device

A future concept built on the same MIROQ technology, designed to deliver lab-grade precision in the palm of your hand.

We envision a future where testing can happen anywhere, anytime – from hospitals and clinics to remote regions or even at home – enabling early disease detection and turning knowledge into real impact. No large equipment or complex infrastructure required.

For: Doctor’s offices, small and mobile clinics

Future application: Home use

Connectivity: Bluetooth, Wifi and USB